Skip to content

A randomized, controlled trial of intermittent hypoxia exposure for treatment of Post-COVID-19 Condition (long COVID)

A randomized, controlled trial of intermittent hypoxia exposure for treatment of COVID-19 patient’s recovery

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070565
Enrollment
Unknown
Registered
2023-04-17
Start date
2023-04-17
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-COVID-19 Condition (long COVID)

Interventions

Intermittent hypoxia exposure:The subjects are alternately exposed to hypoxia (O2 10~12%) for 5 min and 5 min air (O2 21%) during awake, for 5 consecutive cycles and a total of 50-min daily. The inter
Normoxia:The subjects are alternately exposed to compressed air (O2 21%) for 5 min and 5 min air (O2 21%) during awake, for 5 consecutive cycles and a total of 50-min daily. The normoxia exposure last

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) adults aged 18-70 years, male or female; (2) having been infected with confirmed SARSCoV-2 infection three months ago; (3)having persistent symptoms from onset and lasting for at least 4 weeks which cannot be explained by an alternative diagnosis; (4) the body temperature has returned to normal after the acute period treatment, in the recovery period but still have symptoms, such as cough, expectoration, sore throat, fatigue, smell disorder, muscle soreness, etc; or there are still residual imaging features remained after COVID-19 infection; or there are still psychological symptoms remained such as insomnia, anxiety, irritability, sweating, etc; (5) The participant himself signs the informed consent form and agrees to collect the clinical samples.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) COVID-19 patients in the acute phase, especially subjects who need oxygen therapy and other measures to improve body oxygenation; (2) Pregnant women and lactating women; (3) In the acute stage of physical disease, myocardial infarction in the past 3 months, unstable angina pectoris, acute ischemic stroke in the past 6 months; (4) Sually transmitted diseases and fever; (5) Conditions requiring traditional hemodialysis treatment; (6) decompensated chronic renal failure; (7) Hypertension stage III, frequent hypertensive crisis; (8) Severe extracranial blood flow disorders; (9) congenital cardiac and macrovascular anomalies; (10) thrombotic status and thromboembolic complications; (11) primary and secondary polycythemia; (12) hypoxic intolerance; (13) mental retardation or mental disorder; (14) cases of respiratory failure requiring mechanical ventilation; (15) cases of shock; (16) other organ failure; (17) cases of poor survival, only hospice care, or deep coma unresponsive to supportive care within three hours of admission.

Design outcomes

Primary

MeasureTime frame
Symptom score;Six-minute walk test;Radiographic score of chest CT;Lung function test;

Secondary

MeasureTime frame
adverse event;Sleep monitoring results;Anxiety and Depression Scale Scores;Quality of Life Score;

Countries

China

Contacts

Public ContactKe Hu

Renmin Hospital of Wuhan University

huke-rmhospital@163.com+86 18971035988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026